Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in advanced gastric or gastroesophageal junction adenocarcinoma after ≥2 prior chemotherapies
CTR20160019Phase 4Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Jan 2016
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 4 trial of Rivoceranib in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Hengrui Therapeutics. Started Jan 2016; status: completed.
02
Drugs
Rivoceranib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20160019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160019.